2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
848
Carcinoma, Non-Small-Cell Lung
549
Neoplasms
510
Prostatic Neoplasms
501
Lung Neoplasms
312
Colorectal Neoplasms
307
Multiple Myeloma
292
Neoplasm Metastasis
250
Melanoma
241
Ovarian Neoplasms
215
Leukemia, Myeloid, Acute
208
Pancreatic Neoplasms
207
Squamous Cell Carcinoma of Head and Neck
173
Carcinoma, Renal Cell
165
Recurrence
162
Stomach Neoplasms
161
Carcinoma, Hepatocellular
160
Lymphoma
156
Brain Neoplasms
152
Glioblastoma
147
Uterine Cervical Neoplasms
144
Lymphoma, Non-Hodgkin
141
Head and Neck Neoplasms
140
Triple Negative Breast Neoplasms
136
Leukemia, Lymphocytic, Chronic, B-Cell
136
Urinary Bladder Neoplasms
135
Precursor Cell Lymphoblastic Leukemia-Lymphoma
132
Colonic Neoplasms
115
Hematologic Neoplasms
113
Lymphoma, Follicular
112
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Nephroma, Mesoblastic
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA